Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Exablate Clear all
Recruiting Not applicable Interventional

A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects

NCT03028246
View directory record Official record
Conditions
Benign Centrally-Located Intracranial Tumors
Interventions
ExAblate 4000 System
Device
Lead sponsor
InSightec
Industry
Eligibility
5 Years to 22 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Miami, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 4, 2026, 9:24 PM EDT
Withdrawn Phase 2 Interventional

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

NCT05879120
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Pembrolizumab, Exablate MRgFUS + neoadjuvant pembolizumab
Drug · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 4, 2026, 9:24 PM EDT
Recruiting Not applicable Interventional

Focused Ultrasound Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects

NCT06036199
View directory record Official record
Conditions
Cerebral Palsy, Dyskinetic, Secondary Dystonia
Interventions
Focused Ultrasound Pallidotomy
Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 22 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 4, 2026, 9:24 PM EDT
Active, not recruiting Not applicable Interventional

Bilateral Treatment of Medication Refractory Essential Tremor

NCT04112381
View directory record Official record
Conditions
Essential Tremor
Interventions
Exablate Model 4000 Type 1.0/1.1
Device
Lead sponsor
InSightec
Industry
Eligibility
22 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Stanford, California • Baltimore, Maryland • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 4, 2026, 9:24 PM EDT
Recruiting Not applicable Interventional

Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy

NCT07405645
View directory record Official record
Conditions
Head Neck Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Cancer Pain
Interventions
ExAblate Neuro
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 4, 2026, 9:24 PM EDT
Completed Not applicable Interventional Results available

ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease

NCT02263885
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ExAblate Transcranial System
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 4, 2026, 9:24 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

MR Guided Focused Ultrasound Surgery in the Treatment of Breast Fibroadenomas

NCT00147108
View directory record Official record
Conditions
Breast Fibroadenoma
Interventions
ExAblate 2000
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
4
States / cities
Boca Raton, Florida • Boston, Massachusetts • Voorhees Township, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2012 · Synced Sep 4, 2026, 9:24 PM EDT
Recruiting No phase listed Observational

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

NCT04991831
View directory record Official record
Conditions
Tremor Associated With Tremor Dominant Parkinson's Disease
Interventions
Unilateral thalamotomy
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 4, 2026, 9:24 PM EDT
Completed Phase 4 Interventional

The FIRSTT: Comparing MRgFUS(MR-guided Focused Ultrasound) Versus UAE (Uterine Artery Embolization)for Uterine Fibroids.

NCT00995878
View directory record Official record
Conditions
Symptomatic Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
Interventions
Focused ultrasound (MRgFUS), Uterine artery embolization (UAE)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
San Francisco, California • Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 4, 2026, 9:24 PM EDT
Completed Not applicable Interventional

Focused Ultrasound (FUS) Mesencephalotomy for Head & Neck Cancer Pain

NCT03894553
View directory record Official record
Conditions
Cancer of Head and Neck, Pain, Face, Pain, Neck
Interventions
ExAblate Neuro
Device
Lead sponsor
Jeff Elias, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 4, 2026, 9:24 PM EDT
Terminated Not applicable Interventional

Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma

NCT04123535
View directory record Official record
Conditions
Undifferentiated Pleomorphic Sarcoma
Interventions
ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
Device
Lead sponsor
Matthew Bucknor
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 4, 2026, 9:24 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Sonication-based OCD Neurosurgical Intervention Via Capsulotomy

NCT06131502
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Palo Alto, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 4, 2026, 9:24 PM EDT
Terminated Not applicable Interventional Results available

Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors

NCT01965002
View directory record Official record
Conditions
Soft Tissue Neoplasms
Interventions
MRgHIFU, Aspirin, Enoxaparin
Device · Drug
Lead sponsor
Pejman Ghanouni
Other
Eligibility
10 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 4, 2026, 9:24 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

NCT05630209
View directory record Official record
Conditions
Brain Tumor
Interventions
Exablate, Doxorubicin
Device · Drug
Lead sponsor
InSightec
Industry
Eligibility
5 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Miami, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 4, 2026, 9:24 PM EDT
Active, not recruiting Early Phase 1 Interventional

Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

NCT05469009
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease 1
Interventions
Aducanumab, Exablate Model 4000 Type 2, Lecanemab
Drug · Device
Lead sponsor
Ali Rezai
Other
Eligibility
50 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 4, 2026, 9:24 PM EDT
Completed Not applicable Interventional

MR Guided Focused Ultrasound for Treatment of Neuropathic Pain

NCT03111277
View directory record Official record
Conditions
Severe Neuropathic Pain Due to Radiculopathy or Radicular Injury, Spinal Cord Injuries, Phantom Limb Pain
Interventions
Experimental: ExAblate Transcranial treatment
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 4, 2026, 9:24 PM EDT
Terminated No phase listed Observational

ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

NCT01834937
View directory record Official record
Conditions
Pain Resulting From Bone Metastases
Interventions
ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Duarte, California • San Francisco, California • Stanford, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Sep 4, 2026, 9:24 PM EDT
Active, not recruiting Phase 1 Interventional

The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety

NCT05032105
View directory record Official record
Conditions
Anxiety, Medication-refractory Focal-onset Epilepsy
Interventions
Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 4, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor

NCT01304758
View directory record Official record
Conditions
Essential Tremor
Interventions
ExAblate Transcranial MRgFUS System
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2013 · Synced Sep 4, 2026, 9:24 PM EDT
Withdrawn Not applicable Interventional

Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma

NCT04667715
View directory record Official record
Conditions
Glioma
Interventions
Exablate BBBD
Device
Lead sponsor
InSightec
Industry
Eligibility
21 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 4, 2026, 9:24 PM EDT
Recruiting No phase listed Observational

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

NCT05539196
View directory record Official record
Conditions
Movement Disorders, Neurology, Parkinsons Disease
Interventions
Exablate Pallidotomy, Unilateral
Device
Lead sponsor
InSightec
Industry
Eligibility
30 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 4, 2026, 9:24 PM EDT
Completed Phase 1Phase 2 Interventional

Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy

NCT04417088
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Carboplatin, Exablate BBBD
Drug · Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Palo Alto, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 4, 2026, 9:24 PM EDT
Suspended Phase 2 Interventional

A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG

NCT05123534
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
Interventions
SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Combination Product
Lead sponsor
SonALAsense, Inc.
Industry
Eligibility
5 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 4, 2026, 9:24 PM EDT
Active, not recruiting Not applicable Interventional

MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors

NCT00147056
View directory record Official record
Conditions
Brain Tumor
Interventions
ExAblate transcranial system
Device
Lead sponsor
InSightec
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 4, 2026, 9:24 PM EDT